Undoubtedly, ChREBP has a central and pleiotropic role in metabolic regulation, which, in turn, means that its study as a therapeutic target in diseases such as T2DM or fatty liver may involve adverse effects. The gene discussed is MLXIPL; the disease is fatty liver disease.